LRMR

Larimar Therapeutics Reports Third Quarter 2022 Operating and Financial Results

Retrieved on: 
Thursday, November 10, 2022
GLOBE, Review, Marketing, U.S. Securities and Exchange Commission, FA, Food, Nasdaq, Research, Annual report, Technology, Friedreich's ataxia, LRMR, Patent, COVID-19, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Therapy, SEC, Company, Form 10-K, Clinical trial, Terminology, Patient, 1836 U.S. Patent Office fire, Security (finance), Ataxia, FDA, Pharmaceutical industry, Reinsurance, Larimar, MD

Cash of $124.7 million at September 30, 2022 provides projected cash runway into 2H 2024

Key Points: 
  • Cash of $124.7 million at September 30, 2022 provides projected cash runway into 2H 2024
    BALA CYNWYD, Pa., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases,today reported its third quarter 2022 operating and financial results.
  • In September 2022, Larimar raised net proceeds of approximately $75.2 million through an underwritten offering of common stock.
  • Research and development expenses for the third quarter of 2022 were $5.6 million compared to $14.0 million for the third quarter of 2021.
  • General and administrative expenses for the third quarter of 2022 were $2.9 million compared to $2.7 million for the third quarter of 2021.

Larimar Therapeutics Announces Issuance of U.S. Patent Providing Composition of Matter Protection for CTI-1601

Retrieved on: 
Thursday, October 20, 2022
European Medicines Agency, Union, Method, SEC, Therapy, Royal commission, LRMR, Private Securities Litigation Reform Act, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, Annual report, Friedreich's ataxia, Nasdaq, Orphan drug, Form 10-K, Food, Company, Food and Drug Administration, Mitochondrion, Patent, Indiana University, GLOBE, Intellectual property, FDA, European Commission, Pharmaceutical industry, Larimar, MD

BALA CYNWYD, Pa., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases,today announced the issuance of U.S. Patent No.

Key Points: 
  • BALA CYNWYD, Pa., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases,today announced the issuance of U.S. Patent No.
  • The patent, titled, Materials and Methods for Treating Friedreich's Ataxia, provides composition of matter protection for CTI-1601 into at least July 2040.
  • Larimar has an exclusive license to the patent per a prior agreement with Indiana University.
  • This new patent represents a foundational component of our intellectual property portfolio, as it extends our patent protection for CTI-1601 by more than fourteen years, said Carole Ben-Maimon, MD, President and Chief Executive Officer of Larimar.

WORLD CLASS ATHLETES AND LEADERS INCLUDING LRMR VENTURES, SC HOLDINGS, DRAYMOND GREEN, AND KEVIN LOVE TO BUY NEW TEAM IN MAJOR LEAGUE PICKLEBALL

Retrieved on: 
Wednesday, September 28, 2022
People, YouTube, Twitter, City, MLP, Founder CEO, LeBron James, Health, Growth, CMO, LRMR, Program, History, Investment, CEO, Instagram, Pickleball, Founder, Pinterest, Sport, SC, Relevent Sports Group, Milwaukee, TikTok, List of Super Bowl champions, Marketing, List of NBA champions, Multimedia, Bravo, NBA, View, Boilermaker, Online gambling, Group, Facebook, Ryan Serhant

AUSTIN, Texas, Sept. 28, 2022 /PRNewswire/ -- Major League Pickleball is welcoming a new ownership group made up of LRMR Ventures, the family office of global icon LeBron James and entrepreneur and CEO Maverick Carter, investment firm SC Holdings, NBA Champions Draymond Green and Kevin Love, The SpringHill Company CMO Paul Rivera, and Relevent Sports Group co-owner and CEO Daniel Sillman.

Key Points: 
  • We're thrilled to become partners of Major League Pickleball which as a league and sport is just getting started."
  • For more information on Major League Pickleball, visit MajorLeaguePickleball.net and follow Major League Pickleball on Facebook , Twitter , Instagram , TikTok , Pinterest and YouTube .
  • Major League Pickleball is the first of its kind professional team league in the United States, consisting of 12 teams representing the highest level of professional pickleball.
  • For more information on Major League Pickleball, visit MajorLeaguePickleball.net and follow Major League Pickleball on Facebook , Twitter , Instagram , TikTok , Pinterest and YouTube .

Larimar Therapeutics Announces FDA Clearance to Initiate the 25 mg Cohort of a Phase 2 Dose Exploration Trial of CTI-1601 in Friedreich’s Ataxia Patients

Retrieved on: 
Wednesday, September 14, 2022
Phase II, PK, Safety, Time, COVID-19, FA, FDA, Food, ID, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, European Commission, Mitochondrion, Form 10-K, Review, News, LRMR, Therapy, Toxicology, Patient, Clinical trial, NHP, Terminology, Nasdaq, MAD, Orphan drug, European Medicines Agency, Research, Friedreich's ataxia, GLOBE, SEC, Animal, Marketing, PD, Annual report, Communication, Gene expression, Webcast, Pharmaceutical industry, MD, Larimar

BALA CYNWYD, Pa., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the initiation of the 25 mg cohort of a Phase 2, four-week, placebo-controlled, dose exploration trial of CTI-1601 in Friedreich’s ataxia (FA) patients. In a written communication to Larimar, the FDA indicated it was lifting its full clinical hold on the CTI-1601 program and imposing a partial hold. The design of the upcoming Phase 2 trial is identical to the design proposed by Larimar, with the exception of a requirement for the FDA to review data from the 25 mg cohort prior to escalating the dose in the second cohort. Larimar expects to begin the Phase 2 trial in Q4 2022, with top-line data expected in 2H 2023.

Key Points: 
  • We are now working expeditiously to initiate our Phase 2 dose exploration trial next quarter.
  • Patients may be CTI-1601 treatment nave or have previously participated in Larimars Phase 1 single- or multiple ascending dose trials.
  • The trial is designed to enroll approximately 24 30 total patients across two cohorts, with the first cohort of 12 15 patients evaluating a 25 mg dose of CTI-1601.
  • Cohort 1 of the MAD trial, which evaluated a 25 mg dose, explored a daily dosing regimen for only four days.

Larimar Therapeutics Provides Updates on CTI-1601 Clinical Program Following a Type C Meeting with the U.S. Food and Drug Administration and Reports Second Quarter 2022 Operating and Financial Results

Retrieved on: 
Thursday, August 11, 2022
FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, LRMR, FA, GLOBE, NHP, European Medicines Agency, SEC, Clinical trial, MAD, Research, Marketing, Patient, Therapy, COVID-19, Company, Toxicology, Agency, Form 10-K, Mitochondrion, Friedreich's ataxia, Safety, Nasdaq, Type, MD, Royal commission, Time, Orphan drug, Annual report, European Commission, Food, Terminology, Pharmaceutical industry, Commercial property, Reinsurance, Larimar

The Company plans to submit a complete response to the CTI-1601 clinical hold in the third quarter of 2022.

Key Points: 
  • The Company plans to submit a complete response to the CTI-1601 clinical hold in the third quarter of 2022.
  • We look forward to receiving FDA feedback on the complete response and our proposed Phase 2 dose exploration study.
  • Research and development expenses for the second quarter of 2022 were $5.6 million compared to $9.1 million for the second quarter of 2021.
  • General and administrative expenses for the second quarter of 2022 were $3.0 million compared to $3.4 million for the second quarter of 2021.

Canyon Bicycles Attracts Strategic Investment from LRMR Ventures and SC Holdings

Retrieved on: 
Friday, July 29, 2022
Investment, LeBron James, View, Awareness, ISIN, HGC Global Communications, Financial adviser, EUR, Culture, Health, Marketing, Athlete, Multimedia, BEL20, Euronext, YouTube, Technology, Sport, Groupe Bruxelles Lambert, GBL, LRMR, ESG, Growth, SC, Financial services, Online shopping, Road

KOBLENZ, Germany, July 29, 2022 /PRNewswire/ -- Canyon Bicycles GmbH ("Canyon"), world-leading direct-to-consumer manufacturer of premium bikes in Koblenz, Germany, announces a strategic equity investment led by LRMR Ventures, the family office of global icon LeBron James and Maverick Carter, and SC Holdings, a US-based private equity firm focused on market-leading brands.

Key Points: 
  • The strategic investments of LRMR Ventures and SC Holdings, as well as the appointment of Robert Kyncl as Board Director, will help expand Canyon's US presence
    KOBLENZ, Germany, July 29, 2022 /PRNewswire/ -- Canyon Bicycles GmbH ("Canyon"), world-leading direct-to-consumer manufacturer of premium bikes in Koblenz, Germany, announces a strategic equity investment led by LRMR Ventures, the family office of global icon LeBron James and Maverick Carter, and SC Holdings, a US-based private equity firm focused on market-leading brands.
  • Canyon will work with LRMR and SC to increase engagement in the US and in the e-bike category, elevate global brand awareness and deliver the best online shopping experience.
  • SC Holdings founder/Managing Partner Jason Stein added: "Canyon has been a leader in cycling and a pioneer in direct-to-consumer e-commerce for over 20 years.
  • SC Holdings is a private equity and strategic advisory firm with global experience building businesses and executing transactions.

Larimar Therapeutics Announces Presentation at the Upcoming Gordon Research Conference on Neurobiology of Brain Disorders

Retrieved on: 
Thursday, July 28, 2022
Gene expression, GLOBE, FXN, Discovery, Bioinformatics discovery of non-coding RNAs, Therapy, Conference, Expression, Friedreich's ataxia, Neuroscience, Neurodegeneration, Nasdaq, Poster, LRMR, Vaccine

BALA CYNWYD, Pa., July 28, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases,today announced that preclinical studies evaluating CTI-1601s effects on gene expression and neurodegeneration will be featured in a poster at the upcoming Gordon Research Conference on Neurobiology of Brain Disorders .

Key Points: 
  • BALA CYNWYD, Pa., July 28, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases,today announced that preclinical studies evaluating CTI-1601s effects on gene expression and neurodegeneration will be featured in a poster at the upcoming Gordon Research Conference on Neurobiology of Brain Disorders .
  • The conference will take place August 7 12, 2022 at the Rey Don Jaime Grand Hotel in Castelldefels, Spain.
  • The posters presenting author is David Bettoun, Ph.D., Vice President of Discovery and Non-clinical R&D, Larimar Therapeutics.
  • Larimar Therapeutics, Inc.(Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases.

Larimar Therapeutics Announces Upcoming Scientific Conference Presentations

Retrieved on: 
Thursday, June 2, 2022
Neurodegeneration, Therapy, Friedreich's ataxia, Patient, LRMR, Gene expression, Nasdaq, Larimar, Pharmaceutical industry

During the presentation, Dr. Baile will discuss preclinical studies performed in in vitro and in vivo disease models that evaluated CTI-1601s effects on gene expression and neurodegeneration.

Key Points: 
  • During the presentation, Dr. Baile will discuss preclinical studies performed in in vitro and in vivo disease models that evaluated CTI-1601s effects on gene expression and neurodegeneration.
  • Larimar Therapeutics, Inc.(Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases.
  • Larimars lead compound, CTI-1601, is being developedas a potential treatment for Friedreich's ataxia.Larimaralso plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
  • For more information, please visit: https://larimartx.com .

Larimar Therapeutics Reports First Quarter 2022 Operating and Financial Results

Retrieved on: 
Thursday, May 12, 2022
NHP, MOA, Company, Disease, Type, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Toxicology, Research, Annual report, Nasdaq, Patient, Form 10-K, Therapy, Friedreich's ataxia, Clinical trial, COVID-19, Marketing, FDA, Terminology, SEC, LRMR, GLOBE, Pharmaceutical industry, Larimar, MD

BALA CYNWYD, Pa., May 12, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its first quarter 2022 operating and financial results.

Key Points: 
  • - CTI-1601 Type C Meeting to discuss clinical hold has been granted by the U.S. Food and Drug Administration and is scheduled for early in the third quarter of 2022
    - Cash at March 31, 2022 of $62.6 million provides projected cash runway into the third quarter of 2023
    BALA CYNWYD, Pa., May 12, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases,today reported its first quarter 2022 operating and financial results.
  • In February 2022, Larimar received feedback from the U.S. Food and Drug Administration (FDA) regarding the May 2021 clinical hold placed on the CTI-1601 program.
  • Research and development expenses for the first quarter of 2022 were $5.8 million compared to $9.0 million for the first quarter of 2021.
  • General and administrative expenses for the first quarter of 2022 and the first quarter of 2021 were both $3.1 million.

Larimar Therapeutics Reports Fourth Quarter and Full Year 2021 Operating and Financial Results

Retrieved on: 
Friday, March 25, 2022
Company, Therapy, NHP, Frataxin, Form 10-K, Marketing, Clinical trial, European Medicines Agency, Annual report, Skin, Research, SEC, Toxicology, MAD, Ataxia, Medicine, Food, Tissue, Communication, FA, LRMR, Nasdaq, COVID-19, Șaeș, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, GLOBE, EMA, Accounting, Terminology, FDA, Insurance, Friedreich's ataxia, Patient, Pharmaceutical industry, Larimar, MD

BALA CYNWYD, Pa., March 25, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases,today reported its full year 2021 operating and financial results.

Key Points: 
  • BALA CYNWYD, Pa., March 25, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases,today reported its full year 2021 operating and financial results.
  • In May 2021, Larimar reported positive topline data from its Phase 1 Friedreichs ataxia (FA) program.
  • Research and development expenses for the fourth quarter of 2021 were $6.3 million compared to $10.6 million for the fourth quarter of 2020.
  • General and administrative expenses for the fourth quarter of 2021 were $2.8 million compared to $3.8million for the fourth quarter of 2020.